Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Krystal Biotech (KRYS) Equity Ratio (2021 - 2025)

Krystal Biotech (KRYS) has disclosed Equity Ratio for 5 consecutive years, with 0.91 as the latest value for Q4 2025.

  • Quarterly Equity Ratio rose 2.01% to 0.91 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.91 through Dec 2025, up 2.01% year-over-year, with the annual reading at 0.91 for FY2025, 2.01% up from the prior year.
  • Equity Ratio hit 0.91 in Q4 2025 for Krystal Biotech, roughly flat from 0.92 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.97 in Q1 2021 to a low of 0.89 in Q1 2022.
  • Historically, Equity Ratio has averaged 0.93 across 5 years, with a median of 0.93 in 2022.
  • Biggest YoY gain for Equity Ratio was 3.67% in 2022; the steepest drop was 8.52% in 2022.
  • Year by year, Equity Ratio stood at 0.95 in 2021, then fell by 1.33% to 0.94 in 2022, then grew by 1.75% to 0.95 in 2023, then decreased by 5.8% to 0.9 in 2024, then grew by 2.01% to 0.91 in 2025.
  • Business Quant data shows Equity Ratio for KRYS at 0.91 in Q4 2025, 0.92 in Q3 2025, and 0.91 in Q2 2025.